Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2024
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Basilea Pharmaceutica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cresemba® Sales in Latin America Trigger First Sales Milestone Payment to Basilea
Details : Knight will commercialize Cresemba (isavuconazole sulfate) in Latin America, an azole antifungal for treating adult patients with invasive aspergillosis, licensed for regional distribution.
Product Name : Cresemba
Product Type : Other Small Molecule
Upfront Cash : $11.2 million
January 19, 2024
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Basilea Pharmaceutica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Ottawa Hospital Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Escalation For INtraprostatic LEsions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 09, 2023
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Ottawa Hospital Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
Details : Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Product Name : Exelon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2022
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
Details : Exelon Patch (rivastigmine transdermal system) is a class of medications called cholinesterase inhibitors, which is used to manage and treat neurodegenerative disease, specifically dementia, in patients with Alzheimer and Parkinson disease.
Product Name : Exelon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2022
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Rigel Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Knight Enters into Exclusive License Agreements with Rigel to Commercialize Fostamatinib
Details : Knight will be responsible for the development and commercialization rights in Latin America for Tavalisse (fostamatinib), a spleen tyrosine kinase inhibitor for treating immune thrombocytopenia.
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 24, 2022
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Rigel Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia
Details : Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Product Name : Exelon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Miltefosine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Profounda Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Miltefosine is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europ...
Product Name : Impavido
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2021
Lead Product(s) : Miltefosine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Profounda Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Novartis Pharmaceuticals Corporation
Deal Size : $180.0 million
Deal Type : Acquisition
Details : Knight Therapeutics has acquired exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America, as well as an exclusive license to use the intellectual property and the Exelon trademark,...
Product Name : Exelon
Product Type : Other Small Molecule
Upfront Cash : $168.0 million
May 26, 2021
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Novartis Pharmaceuticals Corporation
Deal Size : $180.0 million
Deal Type : Acquisition